机械按压装置在院外心脏骤停中的成本效益
本研究基于一项大型实用性多中心试验的患者层面数据,链接医院统计(HES)行政数据,评估LUCAS-2机械心肺复苏装置与人工胸外按压在成人非创伤性院外心脏骤停中的成本效益。共纳入4471例患者(LUCAS-2组1652例,对照组2819例)。12个月时LUCAS-2组89例(5%)存活,人工按压组175例(6%)存活。在试验内分析及终身时间跨度外推分析中,人工按压均占优,即LUCAS-2组健康结局更差(QALY更低)且健康与社会照护成本更高。结论认为LUCAS-2相比标准人工胸外按压不具有成本效益。
要点
- 12个月生存率:LUCAS-2组89/1652例(5%)vs 人工按压组175/2819例(6%)。
- 在绝大多数分析中(试验内及终身外推),人工胸外按压均占优LUCAS-2。
- LUCAS-2组QALY更低,且健康与社会照护成本更高。
- 作者结论:LUCAS-2在院外心脏骤停中相比标准人工胸外按压不具有成本效益。
适用人群与场景
- 成人非创伤性院外心脏骤停患者。
研究设计与关键结果
- 研究设计:基于大型实用性多中心试验的患者层面数据分析,链接医院统计(HES)行政数据测量医疗资源使用、成本与结局。
- 样本量:4471例患者,LUCAS-2组1652例,对照组2819例。
- 主要结局:12个月生存率LUCAS-2组89例(5%)vs 人工按压组175例(6%)。
- 成本效益:在试验内分析(基于EQ-5D-3L的QALY,12个月随访)及终身时间跨度决策分析模型外推中,绝大多数分析显示人工按压占优LUCAS-2,即LUCAS-2组QALY更低且健康与社会照护成本更高。
证据类型、等级与局限
- 证据类型:基于大型实用性多中心试验的患者层面数据的经济学评价。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在院外心脏骤停中LUCAS-2机械胸外按压装置相比标准人工胸外按压不具有成本效益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To assess the cost-effectiveness of LUCAS-2, a mechanical device for cardiopulmonary resuscitation (CPR) as compared to manual chest compressions in adults with non-traumatic, out-of-hospital cardiac arrest.
METHODS: We analysed patient-level data from a large, pragmatic, multi-centre trial linked to administrative secondary care data from the Hospital Episode Statistics (HES) to measure healthcare resource use, costs and outcomes in both arms. A within-trial analysis using quality adjusted life years derived from the EQ-5D-3L was conducted at 12-month follow-up and results were extrapolated to the lifetime horizon using a decision-analytic model.
RESULTS: 4471 patients were enrolled in the trial (1652 assigned to the LUCAS-2 group, 2819 assigned to the control group). At 12 months, 89 (5%) patients survived in the LUCAS-2 group and 175 (6%) survived in the manual CPR group. In the vast majority of analyses conducted, both within-trial and by extrapolation of the results over a lifetime horizon, manual CPR dominates LUCAS-2. In other words, patients in the LUCAS-2 group had poorer health outcomes (i.e. lower QALYs) and incurred higher health and social care costs.
CONCLUSION: Our study demonstrates that the use of the mechanical chest compression device LUCAS-2 represents poor value for money when compared to standard manual chest compression in out-of-hospital cardiac arrest.
参考来源
- Marti J, Hulme C, Ferreira Z, et al. The cost-effectiveness of a mechanical compression device in out-of-hospital cardiac arrest. Resuscitation. 2017. PMID: 28476479. doi:10.1016/j.resuscitation.2017.04.036
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。